| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/06/2002 | WO2002020483A8 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 06/06/2002 | WO2002020474A3 Resorcinol derivatives |
| 06/06/2002 | WO2002018437A3 Cyclic peptides having melanocortin-4 receptor agonist activity |
| 06/06/2002 | WO2002014314A3 Substituted pyrazoles |
| 06/06/2002 | WO2002014294A3 Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| 06/06/2002 | WO2002012242A3 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 06/06/2002 | WO2002012198A3 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| 06/06/2002 | WO2002011676A3 Method of using diketopiperazines and composition containing them |
| 06/06/2002 | WO2002011551A3 Oil/fat composition |
| 06/06/2002 | WO2002007683B1 Antimicotic nail varnish composition |
| 06/06/2002 | WO2002000906A3 Replication deficient adenoviral tnf vector |
| 06/06/2002 | WO2001096557A3 A human homologue of the dbf4/ask1 protein, nucleic acids, and methods related to the same |
| 06/06/2002 | WO2001093841A3 Barbituric acid analogs as therapeutic agents |
| 06/06/2002 | WO2001090360A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/06/2002 | WO2001090334A3 Drug metabolizing enzymes |
| 06/06/2002 | WO2001090068A3 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases |
| 06/06/2002 | WO2001088116A9 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 06/06/2002 | WO2001087849A3 Modulators of tnf- alpha signaling |
| 06/06/2002 | WO2001087238A3 Induction of apoptosis and cell growth inhibition by protein 4.33 |
| 06/06/2002 | WO2001080860A3 Daily treatment for erectile dysfunction using a pde5 inhibitor |
| 06/06/2002 | WO2001079442A3 Albumin fusion proteins |
| 06/06/2002 | WO2001068643A3 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 06/06/2002 | WO2001064907A3 Lipid metabolism enzymes |
| 06/06/2002 | WO2001064884A3 G12l, a gene associated with the thermal response |
| 06/06/2002 | WO2001052856A3 Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action |
| 06/06/2002 | WO2001049324A3 Novel colloid synthetic vectors for gene therapy |
| 06/06/2002 | WO2001048209B1 Genes identified as required for proliferation of e. coli |
| 06/06/2002 | WO2001044207B1 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 06/06/2002 | WO2001036645A3 Serine/threonine kinase and serine protease polypeptides and nucleic acids encoding same |
| 06/06/2002 | WO2001003684A3 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 06/06/2002 | WO2000024782A3 Modified peptides, comprising an fc domain, as therapeutic agents |
| 06/06/2002 | US20020069422 Proteins for use in the treatment of trypanosome infection, cancer, inflammation and immunological defects |
| 06/06/2002 | US20020068825 Polypeptide for use in the treatment of nervous system disorders |
| 06/06/2002 | US20020068763 N-substituted-N'-substituted urea derivative is used as a tumor necrosis factor-alpha production inhibitory agent and a therapeutical agent for autoimmune diseases |
| 06/06/2002 | US20020068758 Novel orally active iron (III) chelators |
| 06/06/2002 | US20020068756 Inhibition of phosphodiesterase; 3-carbocyclic(alkyl)oxy-2-aryl(alkyl)aminocarbonyl-1-aryl(alkyl)indole or azaindole derivatives |
| 06/06/2002 | US20020068753 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 06/06/2002 | US20020068750 Mitochondria protecting agents for treating mitochondria associated diseases |
| 06/06/2002 | US20020068748 Diazabicyclooctane derivatives and therapeutic uses thereof |
| 06/06/2002 | US20020068746 Pyrrolo[2,3-d]pyrimidine compounds |
| 06/06/2002 | US20020068744 Interacting with tubulin and microtubules and promoting microtubule polymerization |
| 06/06/2002 | US20020068737 Antagonists for human alpha 1a receptors; lowering intraocular pressure; inhibiting cholesterol synthesis; relaxing lower urinary tract tissue; treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, etc. |
| 06/06/2002 | US20020068735 Progesterone receptor antagonist; inhibiting breast, uterine, ovarian, endometrial, or prostate cancer |
| 06/06/2002 | US20020068706 Inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, can be used to control proliferation and/or differentiation of cells |
| 06/06/2002 | US20020068705 Sugar derivatives of indolocarbazoles; exhibit topoisomerase-I activity |
| 06/06/2002 | US20020068702 Containing eleven amino acid residues |
| 06/06/2002 | US20020068696 Modulating proliferation and apoptotic state of cells using agents that modulate the expression and/or activity of TRADE family polypeptides. |
| 06/06/2002 | US20020068692 Administration a melatonin blocker to patients with disorders associated with altered dopamine function; preclinical diagnosis by administering melatonin to induce a mild transient form of the disorder |
| 06/06/2002 | US20020068323 Nucleotide sequences which code polypeptide for use in human therapeutics ad diagnostics |
| 06/06/2002 | US20020068273 Mimetics and inhibitors of the interaction between Vpr (HIV vIral protein of regulation) and ANT (mitochondrial adenine nucleotide translocator) |
| 06/06/2002 | US20020068102 Use of dietary supplement includes juice from fruit of Morinda citrifolia to scavange lipid hydroperoxides and superoxide anion free radicals within the human body |
| 06/06/2002 | US20020068096 Antimonocytic activity of betel leaf extracts |
| 06/06/2002 | US20020068083 Oil-free; bioavailability; useful as immunosuppressive agents, parasiticides, and agents for the reversal of multi-drug resistance |
| 06/06/2002 | US20020068065 Pharmaceutical composition having specific water activity |
| 06/06/2002 | US20020068062 Inhibitors of the formation of soluble human CD23 |
| 06/06/2002 | US20020068061 Antibody inhibits heparanase activity; prevent angiogenesis, cell proliferation, tumor cell proliferation, invasion of circulating tumor cells, metastases, inflammation and autoimmune conditions |
| 06/06/2002 | US20020068059 Modified human C3 protein for forming said convertase; use in depleting levels of complement pathway protein; preventing transplant rejection |
| 06/06/2002 | US20020068045 Such as neural progenitor cells capable of giving rise to mature somatic cells including neural cells and/or glial cells recognizable by expression of specific markers |
| 06/06/2002 | EP1144454A3 Modified peptides as therapeutic agents |
| 06/06/2002 | DE10060388A1 Verwendung von Pyrazolo [4,3-d]pyrimidinen Use of pyrazolo [4,3-d] pyrimidines |
| 06/06/2002 | DE10058596A1 Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung Method for screening chemical compounds for modulating the interaction of an EVH1 domain or a protein having an EVH1 domain with an EVH1-binding domain or a protein having an EVH1-binding domain and a method for the detection of said interaction |
| 06/06/2002 | DE10040381C1 Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung Perfluoroalkyl-containing complexes with sugar residues, processes for their preparation and their use |
| 06/06/2002 | CA2791831A1 Rna interference mediating small rna molecules |
| 06/06/2002 | CA2457925A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/06/2002 | CA2436941A1 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain |
| 06/06/2002 | CA2433665A1 Projection against mycobacterial infections |
| 06/06/2002 | CA2430924A1 Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
| 06/06/2002 | CA2430745A1 Master bone formation transcription factor: compositions and methods of use |
| 06/06/2002 | CA2430489A1 Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| 06/06/2002 | CA2430485A1 Cytonkine receptor zcytor19 |
| 06/06/2002 | CA2430409A1 Bisubstituted carbocyclic cyclophilin binding compounds and their use |
| 06/06/2002 | CA2430354A1 4-6-diphenyl pyridine derivatives as antiinflammatory agents |
| 06/06/2002 | CA2430343A1 1,4-disubstituted piperazine derivatives useful as uro-selective .alpha.1-adrenoceptor blockers |
| 06/06/2002 | CA2430341A1 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 06/06/2002 | CA2430331A1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 06/06/2002 | CA2430311A1 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | CA2430309A1 Combination of gaba agonists and aldose reductase inhibitors |
| 06/06/2002 | CA2430296A1 Anti-proliferative drugs |
| 06/06/2002 | CA2430269A1 Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| 06/06/2002 | CA2430257A1 Transforming growth factor-beta-related molecules and uses thereof |
| 06/06/2002 | CA2430239A1 A method of treating cancer |
| 06/06/2002 | CA2430133A1 Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| 06/06/2002 | CA2429892A1 Benzothiophene derivative compounds, process of preparation and use thereof |
| 06/06/2002 | CA2429833A1 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 06/06/2002 | CA2429814A1 Rna interference mediating small rna molecules |
| 06/06/2002 | CA2429803A1 Neutral and anionic colloidal particles for gene delivery |
| 06/06/2002 | CA2429801A1 Behavior chemotherapy |
| 06/06/2002 | CA2429615A1 Determination of risk and treatment of complications of prematurity |
| 06/06/2002 | CA2429599A1 Use of b7rp1 antagonists in ige-mediated disorders |
| 06/06/2002 | CA2429469A1 Human elongase genes and uses thereof |
| 06/06/2002 | CA2429382A1 Indole-type inhibitors of p38 kinase |
| 06/06/2002 | CA2428018A1 Tetrapartate prodrugs |
| 06/06/2002 | CA2425892A1 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof |
| 06/06/2002 | CA2422729A1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 06/05/2002 | EP1211313A2 Modulation of PDE11A activity |
| 06/05/2002 | EP1211249A1 Novel thiazine or pyrazine derivatives |
| 06/05/2002 | EP1211247A1 Acylamino cyclopropane derivatives |
| 06/05/2002 | EP1211242A1 Prostaglandin derivatives |
| 06/05/2002 | EP1211240A1 Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof |
| 06/05/2002 | EP1210951A2 Combination for treating andropause containing estrogen agonists/antagonists and testosterone |